To follow the efficiency in treating the obsessive-compulsive disorders in higher dosages of Asentra and low dosages of Olanzepine as an augment of the pharmacological treatment in the obsessive-compulsive symptoms in these patients.

During the research we included 30 patients with long-term obsessive-compulsive symptoms. They were chosen randomly, treated in an out-patient clinic as well as in the Psychiatric clinic. The patients were of both sexes, aged 25-45. In all patients serious somatic diseases were excluded. They were observed by HAMD, HAS, 18 PF(18 Personality Factor-Katel), Scale for measuring the obsession, compulsion and schizophrenia and it was done twice: in the beginning and after three months constant treatment with Asentra tablets in dosages of 100-300mg and Zalasta tablets in dosages of 2,5-5mg per day.

In 12 patients there was an improvement which resulted in score decline of the HAS, HAMD, and 18 PF (18 Personality Factor-Katel). In 8 patients there was a slight improvement. And in 10 patients there was no significant improvement.

High dosages of Asentra given in combination with Olazepine for anxiety treatment and as an augment of the anti-depressive are efficient and safe in treating patients with obsessive-compulsive disorders.